Pharmaceutical

FDA awards GSA breakthrough status for relapsed osteosarcoma treatment

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Jan 8, 2025 - 06:00
FDA awards GSA breakthrough status for relapsed osteosarcoma treatment
GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.
Read the original article

Tags:

Previous Article

Calls for increased education and support for sickle cell blood therapy in US

Next Article

Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AI will severely impact almost a fifth of jobs, Indeed says

AI will severely impact almost a fifth of jobs, Indeed ...

Oct 21, 2023

Shorla Oncology’s IMKELDI approved by FDA for leukaemia cancers

Shorla Oncology’s IMKELDI approved by FDA for leukaemia...

Nov 27, 2024

Listen: Messy PBM conflicts, debatable vaccines, & the future of flu season

Listen: Messy PBM conflicts, debatable vaccines, & the ...

Jun 22, 2023